Targeting tumor vulnerabilities associated with loss of heterozygosity

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Colorectal cancer (CRC) presents significant therapeutic challenges.
• Genetic alterations, such as N-acetyltransferase 2 (NAT2) loss of heterozygosity (LOH), are implicated in CRC development and progression.
• Targeting specific genetic vulnerabilities in CRC offers a promising therapeutic avenue.

Purpose of the Study:

• To investigate the potential of targeting NAT2 LOH in colorectal cancer.
• To identify and characterize a small molecule capable of inhibiting the growth of colorectal tumors with impaired NAT2 activity.

Main Methods:

• Screening for small molecules that affect colorectal cancer cells with NAT2 alterations.
• In vitro and in vivo studies to assess the efficacy of identified compounds.
• Comparative analysis of tumor growth in models with varying NAT2 activity levels.

Main Results:

• A novel small molecule was identified that targets NAT2 LOH in over 4% of colorectal cancers.
• The compound significantly impairs the growth of colorectal tumors exhibiting slow NAT2 activity.
• Tumor growth was reduced by approximately 50% in NAT2-compromised models compared to wild-type.

Conclusions:

• Targeting NAT2 LOH represents a viable therapeutic strategy for a subset of colorectal cancer patients.
• The identified small molecule demonstrates significant preclinical efficacy against NAT2-deficient colorectal tumors.
• Further clinical investigation of this compound is warranted for the treatment of specific colorectal cancer subtypes.